Titan Pharmaceuticals Inc Cash Flow Conversion Efficiency
Titan Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Titan Pharmaceuticals Inc (TTNP) has a cash flow conversion efficiency ratio of -0.244x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-680.00K) by net assets ($2.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Titan Pharmaceuticals Inc (1995–2024)
Cash flow conversion efficiency of Titan Pharmaceuticals Inc from 1995 to 2024. This chart illustrates how Titan Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Titan Pharmaceuticals Inc for real-time trading data and today's change.
Titan Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Titan Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Titan Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Titan Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see TTNP market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Avenir Telecom S.A
PA:AVT
|
-3.784x |
|
VOLT RESOURCES LTD
F:R8L
|
N/A |
|
Eo2 Société Anonyme
PA:ALEO2
|
-0.035x |
|
The North American Income Trust plc
LSE:NAIT
|
0.017x |
|
Search Minerals Inc
V:SMY
|
-0.011x |
|
BoMill AB
ST:BOMILL
|
-0.433x |
|
Fathom Holdings Inc
NASDAQ:FTHM
|
-0.187x |
|
Scandinavian Brake Systems A/S
CO:SBS
|
-0.012x |
Annual Cash Flow Conversion Efficiency for Titan Pharmaceuticals Inc (1995–2024)
The table below shows the annual cash flow conversion efficiency of Titan Pharmaceuticals Inc from 1995 to 2024. Review TTNP free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.44 Million | $-3.88 Million | -1.590x | -48.93% |
| 2023-12-31 | $6.64 Million | $-7.09 Million | -1.068x | +82.22% |
| 2022-12-31 | $1.36 Million | $-8.18 Million | -6.004x | -290.52% |
| 2021-12-31 | $5.14 Million | $-7.90 Million | -1.537x | +68.44% |
| 2020-12-31 | $3.53 Million | $-17.20 Million | -4.871x | +54.81% |
| 2019-12-31 | $1.43 Million | $-15.45 Million | -10.778x | -773.27% |
| 2018-12-31 | $6.83 Million | $-8.43 Million | -1.234x | +91.89% |
| 2017-12-31 | $857.00K | $-13.04 Million | -15.214x | -3288.97% |
| 2016-12-31 | $13.19 Million | $6.29 Million | 0.477x | +144.67% |
| 2015-12-31 | $6.99 Million | $-7.47 Million | -1.068x | -56.82% |
| 2014-12-31 | $8.61 Million | $-5.87 Million | -0.681x | +59.96% |
| 2013-12-31 | $5.76 Million | $-9.80 Million | -1.701x | -2050.04% |
| 2012-12-31 | $-23.13 Million | $1.83 Million | -0.079x | -110.98% |
| 2011-12-31 | $-20.08 Million | $-14.48 Million | 0.721x | -6.29% |
| 2010-12-31 | $-6.05 Million | $-4.66 Million | 0.769x | -97.05% |
| 2009-12-31 | $-207.00K | $-5.41 Million | 26.121x | +285.55% |
| 2008-12-31 | $1.80 Million | $-25.34 Million | -14.078x | -2364.45% |
| 2007-12-31 | $26.59 Million | $-15.19 Million | -0.571x | +50.72% |
| 2006-12-31 | $11.65 Million | $-13.50 Million | -1.159x | +16.04% |
| 2005-12-31 | $16.60 Million | $-22.92 Million | -1.381x | -101.83% |
| 2004-12-31 | $34.95 Million | $-23.91 Million | -0.684x | -18.17% |
| 2003-12-31 | $45.67 Million | $-26.44 Million | -0.579x | -42.27% |
| 2002-12-31 | $71.98 Million | $-29.29 Million | -0.407x | -200.24% |
| 2001-12-31 | $101.37 Million | $-13.74 Million | -0.136x | -19.42% |
| 2000-12-31 | $115.98 Million | $-13.16 Million | -0.113x | +52.62% |
| 1999-12-31 | $45.50 Million | $-10.90 Million | -0.240x | +80.62% |
| 1998-12-31 | $10.60 Million | $-13.10 Million | -1.236x | -420.28% |
| 1997-12-31 | $18.40 Million | $7.10 Million | 0.386x | +145.02% |
| 1996-12-31 | $12.60 Million | $-10.80 Million | -0.857x | -145.85% |
| 1995-12-31 | $-4.60 Million | $-8.60 Million | 1.870x | -- |
About Titan Pharmaceuticals Inc
As of October 1, 2025, Titan Pharmaceuticals, Inc. was acquired by KE Sdn Bhd, in a reverse merger transaction. Titan Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development of therapeutics for the treatment of chronic diseases. Titan Pharmaceuticals, Inc. was founded in 1991 and is based in New York, New York.